$0.19-6.5%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 10, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Profit | -$7.6M | -$9.7M | +21.35% |
| Profit per share | -$0.08 | -$0.10 | +20.00% |
| Free Cash Flow | -$6.6M | -$6.6M | -0.01% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Context Therapeutics Inc. reported on November 10, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Given the challenging market conditions for emerging companies, the increasingly competitive landscape for breast cancer treatments, and recent study findings, we have decided to discontinue the development of ONA-XR,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Therapeutics ® Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company committed to advancing medicines for solid tumors. Context is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors, currently in preclinical development. Context is headquartered in Philadelphia.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Context Therapeutics Inc.’s Item 2.02 8-K filed March 22, 2023; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.